All News

heart-attack.jpg

Inflammatory Conditions Up the Risk of Premature Myocardial Infarction

Jack Cush, MD

The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.

Read Article
RheumNow Podcast square

RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.

Read Article
RA ILD RTX lung

Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease

Jack Cush, MD

There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.

Read Article
Lungs ILD

Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Jack Cush, MD

Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adul

Read Article
RheumNow Podcast square

RheumNow Podcast – Pounds of Prevention (3.5.2021)

Jack Cush, MD

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Read Article
RheumNow Podcast square

RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)

Jack Cush, MD

Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.

Read Article
263 RA patients with ILD were treated w/ Abatacept (ABA mono, ABA+MTX or ABA+nonMTX) - all improved their DAS28, stablized their FVC, DLCO, CHest CT; Only difference was that steroid sparing best when ABA used in combo. https://t.co/11vJCWOdSG https://t.co/yMF6imuFMV

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 32 studies shows most forms of arthritis assoc w/ incr risk of CVA (ischemic stroke: RR=1.53 or hemorrhagic stroke: RR=1.45), esp for RA (RR=1.38), AS (RR=1.49), PsA (RR=1.33), gout (RR=1.4) --risk higher with age <45 years (RR=1.46) https://t.co/YDiebrqtbi

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease https://t.co/2P0tdxvZD2 https://t.co/7gfE1CPSEx

Links:

Dr. John Cush RheumNow ( View Tweet)
Leading the Rheumatoid Arthritis pod with discussions on pneumonia and RA and interstitial lung disease in RA. #RNL2021 https://t.co/psxMTHsOva
Dr. John Cush RheumNow ( View Tweet)
Top 4 arthritis types that significantly increase the risk of CVA: 1) RA (RR=1.38), 2) ankylosing spondylitis (RR=1.49), 3) psoriatic arthritis (RR=1.33) & gout (RR=1.4). With these, the risk was higher in younger (<45 yrs) (RR = 1.46), not older (>65) https://t.co/Snb6OrtZJH

Links:

Dr. John Cush RheumNow ( View Tweet)

Other recommendations from Dr Calabrese @CCalabreseDO today @AWIRGROUP Summit. #WomeninRheum education everyone. https://t.co/YahmODVEw2
WOMEN IN RHEUM AWIRGROUP ( View Tweet)
#RA associated interstifial lung dz has incidence of 1-5 per 1,000 PYs and prevalence as high as 67%; risk factors; age, male sex, Dz duration, CCP Abs; w/ age as best predictor of mortality. There is no clear drug interventions that helps RA-ILD https://t.co/zJvWqt0w6L

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease https://t.co/6A4muejeH9 https://t.co/xQbIoEEscv

Links:

Dr. John Cush RheumNow ( View Tweet)
Today the FDA approved tocilizumab (Actemra) for use in Systemic Sclerosis-Associated Interstitial Lung Disease for "Slowing the rate of decline in pulmonary function in adult patients with SSc-ILD" Rec dose is 162 mg SC q week (IV dose not approved) https://t.co/HXTRPiYEfZ

Links:

Dr. John Cush RheumNow ( View Tweet)

While RA incurrs a 2 fold risk of CHF; the use of HCQ does not add to a CHF risk. Mayo nested case-control study, compared RA w/ CHF vs nonCHF RA pts, showing HCQ use, nor duration of use, failed to increase CHF (OR: 0.96).https://t.co/Tx9jr07C7i

Links:

Dr. John Cush RheumNow ( View Tweet)

We are excited to announce that Jeff Sparks ( @jeffsparks) will be leading a discussion on ILD in RA at RheumNow Live this March. Register to attend today. https://t.co/uwxOVh142F https://t.co/bnittqkhKQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Lung Preservation w/ Tocilizumab in Early Systemic Sclerosis Arthritis & Rheumatology has published the results of a subanalysis from TCZ clinical trials showing that Il-6 inhibition is related with preservation of lung function patients with early SSc. https://t.co/2BwWQWEkri https://t.co/pjVc8YTDwU

Links:

Dr. John Cush RheumNow ( View Tweet)
CTD associated pulmonary HTN has improved sincd 2010. Metanalysis of 11 RCTs (4,329 pts) & 19 registries (9,739 pts); 5 RCTs find PAH Rx assoc w/ 36% lower mortality/morbidity. Registry data shows better PAH survival since 2010 (73% vs 65% @3yrs) https://t.co/0BkO70AQfi

Links:

Dr. John Cush RheumNow ( View Tweet)

Analysis of incident #RA in UK Clinical Practice registry shows recent prednisone >=7.5mg/d is assoc w/ hypertension in RA. In 17760 RA pts, 42% were Rx steroids; recent GC yielded a 17% increase in HTN (HR 1.17); only >7.5mg/D implicated https://t.co/qUKs2oZZUV https://t.co/pWmD4nKs6U

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×